Gene therapy AB-1005 found safe in Phase 1b Parkinson’s trial
Treatment with AB-1005 (AAV2-GDNF), AskBio’s investigational gene therapy, was safe and well tolerated among patients with mild to moderate…
Articles by Andrea Lobo
New imaging technology may help diagnose neurological conditions
Targeted ocular spectroscopy, a technology that allows real-time imaging of the back of the eye (or eye fundus) while observing…
Organoid model can replicate neural network of human ‘reward system’
Researchers have developed a three-dimensional brain organoid — a “mini-organ” model of the brain — that replicates a human neural…
NeuroOne’s ablation system cleared by FDA for neurological disorders
The U.S. Food and Drug Administration (FDA) has cleared NeuroOne’s OneRF Ablation System, a brain electrode-guided tool employed in…
Amneal to market Ongentys, for Parkinson’s off periods, in US
Amneal Pharmaceuticals and Bial have entered into a licensing agreement giving Amneal exclusive rights to market…
Trial of buntanetap for early-stage Parkinson’s nears end
Annovis Bio has announced the last patient completed the final visit in its Phase 3 clinical trial testing buntanetap…
Aspen Neuroscience VP honored for work on potential stem cell therapy
Andrés Bratt-Leal, a co-founder of Aspen Neuroscience who is leading work there on a potential stem cell therapy…
1st patient dosed in Phase 2 trial testing vaccine for Parkinson’s
The first patient has been dosed in a Phase 2 clinical trial testing AC Immune’s ACI-7104.056, an investigational vaccine…
Buntanetap lowered TDP-43 blood levels in people with Parkinson’s
Buntanetap significantly reduced the levels of TDP-43 protein in the blood of people with Parkinson’s disease who participated in…
$3.9M NIH grant aims to improve palliative care for Parkinson’s
A five-year project funded by a $3.9 million National Institutes of Health (NIH) research grant will study how team-based palliative…